Related Experiment Video

Updated: May 10, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets

Begoña Mellado1, Mercedes Marin Aguilera, Maria Veronica Pereira

  • 1Medical Oncology Department, ICMHO, Laboratory of Traslational Oncology, IDIBAPS, Hospital Clinic, Barcelona, Spain. bmellado@clinic.ub.es

Archivos Espanoles De Urologia
|June 25, 2013
PubMed

Insights

Prostate cancer initially responds to androgen suppression therapy. However, castration-resistant prostate cancer (CRPC) develops due to androgen receptor (AR) signaling, leading to new therapeutic strategies targeting AR.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Prostate cancer relies on androgen receptor (AR) signaling for survival.
  • Androgen suppression therapy is a primary treatment for metastatic prostate cancer.
  • Most patients develop resistance, progressing to castration-resistant prostate cancer (CRPC).

Purpose of the Study:

  • To review mechanisms of AR-driven resistance to androgen suppression in prostate cancer.
  • To explore how these resistance mechanisms inform new therapeutic strategies.
  • To highlight advancements in targeting AR signaling in CRPC.

Main Methods:

  • Literature review of studies on AR signaling in prostate cancer.
  • Analysis of elucidated mechanisms of androgen deprivation resistance.
  • Synthesis of information on novel agents targeting the AR pathway.

Main Results:

  • CRPC progression is frequently mediated by enhanced AR signaling.
  • Mechanisms include AR mutations, amplification, overexpression, intracrine androgen synthesis, cofactor changes, and cross-talk.
  • New hormonal therapies targeting AR signaling improve patient survival.

Conclusions:

  • Understanding AR signaling mechanisms is crucial for overcoming resistance in prostate cancer.
  • Targeting AR pathway alterations is key to developing effective CRPC treatments.
  • Novel therapeutic strategies are emerging to combat AR-driven resistance.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...